By December 31, 2031, will a peer reviewed, randomised controlled trial or a FDA reviewed NDA which indicated longevity for this drug is published in a top tier medical journal confirm that on-label usage of Rapamycin in healthy individuals aged 50 and above produces a statistically significant increment in median lifespan or there is a measurable decrement of biological ageing than it earlier was, compared to placebo, with results meeting p-value of less than 5% (0.05).

Open on Seer · accepts answers from Tue 31 Dec, 00:00 UTC · OddsFlow orders stop filling the moment the question gets its first answer. Place an order on this market